Juno Therapeutics CEO Bishop on Immunotherapy

The video discusses the development and challenges of CART and TCR cell therapies for cancer treatment. It highlights the importance of market timing, the competition between companies like Juno and Kite, and the difficulties in treating acute lymphoblastic leukemia. Safety concerns and the potential impact of healthcare policies on these therapies are also addressed. The video concludes with a discussion on the pricing and value of these treatments in the healthcare system.

What is the significance of the JCAR 17 compound in lymphoma treatment?

What are the potential costs associated with CAR T cell therapies when they come to market?

How might the dismantling of Obamacare impact the development and reimbursement of cancer treatments?